Side-by-side comparison of mechanisms, dosing, interactions, and stacking potential.
| Lion's Mane (Hericium erinaceus) | Modafinil | |
|---|---|---|
| Category | Nootropics | Nootropics |
| Standard Dose | 500-3000 mg/day of fruiting body extract (standardized to >30% polysaccharides) or 1000-3000 mg/day of mycelium extract (erinacine-enriched) | 100-200 mg once daily (for educational context only — prescription medication in most jurisdictions) |
| Timing | Morning or split morning/afternoon. With or without food. Effects are cumulative — expect 2-4 weeks before noticeable cognitive benefit. | Early morning to avoid insomnia; 1 hour before desired peak alertness. With or without food (food slows absorption by ~1 hour but does not reduce bioavailability). Half-life is approximately 12-15 hours. |
| Cycle Duration | Ongoing; no cycling strictly required, though some users cycle 8 weeks on, 2 weeks off | Not typically cycled in clinical use. Some off-label users cycle to maintain sensitivity (5 days on, 2 off; or as-needed use). |
| Evidence Level | moderate_human | strong_human |
Contains hericenones (fruiting body) and erinacines (mycelium) that stimulate nerve growth factor (NGF) synthesis in glial cells via activation of the JNK pathway. Erinacines cross the blood-brain barrier via passive diffusion and act as potent neurotrophin-stimulating compounds, activating the TrkA receptor and downstream ERK1/2 signaling cascades to promote hippocampal neurogenesis and synaptic plasticity. Also demonstrates anti-inflammatory activity through suppression of NF-kB and upregulation of BDNF expression.
500-3000 mg/day of fruiting body extract (standardized to >30% polysaccharides) or 1000-3000 mg/day of mycelium extract (erinacine-enriched)
Morning or split morning/afternoon. With or without food. Effects are cumulative — expect 2-4 weeks before noticeable cognitive benefit.
Ongoing; no cycling strictly required, though some users cycle 8 weeks on, 2 weeks off
Atypical eugeroic (wakefulness-promoting agent) that primarily inhibits the dopamine transporter (DAT), increasing extracellular dopamine in the prefrontal cortex and nucleus accumbens. This primary action cascades through multiple systems: indirect activation of orexinergic neurons in the lateral hypothalamus via potentiation of glutamatergic transmission; downstream stimulation of histaminergic neurons in the tuberomammillary nucleus (via orexin-mediated disinhibition of GABAergic inputs); and enhancement of norepinephrine release in the locus coeruleus. The net effect is broad-spectrum arousal without the peripheral sympathomimetic effects of classical stimulants.
100-200 mg once daily (for educational context only — prescription medication in most jurisdictions)
Early morning to avoid insomnia; 1 hour before desired peak alertness. With or without food (food slows absorption by ~1 hour but does not reduce bioavailability). Half-life is approximately 12-15 hours.
Not typically cycled in clinical use. Some off-label users cycle to maintain sensitivity (5 days on, 2 off; or as-needed use).
Take our free assessment to get personalized recommendations based on your health goals, current stack, and biomarkers.
Get Your Free Protocol →or take the assessment →